je.st
news
Teva: New Generic Launches Will Benefit Earnings
2015-01-07 20:18:26| Biotech - Topix.net
Recently, Teva has been authorized by the US Food Drug and Administration to introduce the generic counterpart of Diovan "Valsartan" tablets in the US market. The anticipated elevation in earnings is calculated to be $29 million.
Tags: benefit
generic
earnings
launches
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||